A Carnegie Mellon University-led team has received up to $28.5 million to develop a functional, 3D bioprinted liver for patients with acute liver failure. The temporary, immune-compatible liver is designed to support the regeneration of a patient’s own liver, reducing the need for full organ transplants.
A Carnegie Mellon University-led team has secured an award of up to $28.5 millionOpens in new window from the Advanced Research Projects Agency for Health (ARPA-H) to develop a functional, 3D bioprinted liver for patients with acute liver failure. The project, called LIVE, or Liver Immunocompetent Volumetric Engineering, aims to provide a temporary liver that supports regeneration of a patient’s own liver, reducing the need for full organ transplants. The project is under ARPA-H’s Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program, which is led by ARPA-H Program Manager Ryan Spitler, Ph.D.
LIVE addresses a major public health challenge. Each year in the United States, about 100,000 organ transplants are performed, while another 100,000 people remain on transplant waiting lists. Millions more would benefit from organ replacement, but do not qualify for a transplant… Continue reading.
AIMBE

